Eli Lilly and Co (NYSE:LLY) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $75.50 and last traded at $76.18, with a volume of 4498367 shares traded. The stock had previously closed at $76.72.

Several research analysts have recently issued reports on LLY shares. Barclays boosted their price objective on shares of Eli Lilly and from $90.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, October 13th. Piper Jaffray Companies restated a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a report on Friday, October 13th. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a report on Monday, October 16th. Leerink Swann boosted their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Finally, Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a report on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Hold” and a consensus price target of $92.02.

The stock has a market capitalization of $81,710.00, a PE ratio of -371.05, a P/E/G ratio of 1.43 and a beta of 0.23. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The company had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. During the same period in the prior year, the business earned $0.95 earnings per share. Eli Lilly and’s quarterly revenue was up 7.0% on a year-over-year basis. sell-side analysts expect that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 3.03%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is currently -1,040.00%.

In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of the stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now owns 4,130 shares in the company, valued at $334,901.70. The disclosure for this sale can be found here. Insiders sold 261,613 shares of company stock worth $22,894,997 over the last 90 days. 0.20% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Beach Investment Management LLC. bought a new stake in Eli Lilly and in the second quarter valued at approximately $400,000. LMR Partners LLP bought a new stake in Eli Lilly and in the second quarter valued at approximately $1,672,000. Dowling & Yahnke LLC increased its stake in Eli Lilly and by 0.9% in the second quarter. Dowling & Yahnke LLC now owns 61,575 shares of the company’s stock valued at $5,068,000 after purchasing an additional 544 shares in the last quarter. State of Wisconsin Investment Board increased its stake in Eli Lilly and by 16.5% in the second quarter. State of Wisconsin Investment Board now owns 1,046,784 shares of the company’s stock valued at $86,150,000 after purchasing an additional 148,360 shares in the last quarter. Finally, NewSquare Capital LLC increased its stake in Eli Lilly and by 5.5% in the second quarter. NewSquare Capital LLC now owns 13,376 shares of the company’s stock valued at $1,101,000 after purchasing an additional 702 shares in the last quarter. Institutional investors and hedge funds own 76.45% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/02/08/eli-lilly-and-lly-sets-new-1-year-low-at-75-50.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.